The B4GALT1 Knockout CAL-27 Polyclonal Cells represent a targeted CRISPR/Cas9-mediated gene disruption product generated in the human tongue squamous cell carcinoma line CAL-27. This polyclonal population, derived after editing without single?cell cloning, offers a heterogeneous loss-of-function model enabling the study of B4GALT1-dependent processes in an epithelial cancer context. The product provides a tool for dissecting the role of beta-1,4-galactosyltransferase in glycosylation pathways, cell-ECM adhesion, and tumor metastasis, without claiming monoclonality or complete gene inactivation.
The host CAL-27 cell line, originally established from a male patient, is a widely employed model of oral squamous cell carcinoma. CAL-27 cells exhibit epithelial characteristics and are routinely utilized to investigate invasion, metastasis, and drug responsiveness. Their robust growth and well-characterized malignant properties make them suitable for functional studies examining the molecular underpinnings of oral cancer progression, particularly processes reliant on cell-matrix interactions and glycosylation alterations.
B4GALT1 encodes a key glycosyltransferase that catalyzes the transfer of galactose from UDP-galactose to N-acetylglucosamine (GlcNAc), forming N-acetyllactosamine on glycoproteins and glycolipids. This activity is central to N-glycan biosynthesis, O-glycosylation, and glycosphingolipid metabolism. The enzyme also acts as an adhesion molecule, binding extracellular matrix components laminin and fibronectin, and interacts with LALBA, collagen IV, and E-cadherin. Its expression is regulated by upstream factors including TGFB1, EGF, SNAI1, ZEB1, and prolactin. Downstream, B4GALT1-mediated glycosylation of integrin beta1 and EGFR modulates cell adhesion and FAK signaling, linking glycosylation to mechanotransduction and migration.
In the CAL-27 background, B4GALT1 knockout disrupts the biosynthesis of N-acetyllactosamine, impairing the glycosylation of key adhesion receptors and matrix proteins. This perturbation likely attenuates cell-ECM adhesion and migratory capacity, as B4GALT1 is implicated in metastatic dissemination through its effects on integrin activation and focal adhesion kinase (FAK) signaling. Consequently, the model is relevant for interrogating how aberrant glycosylation contributes to oral squamous cell carcinoma invasiveness and for testing hypotheses regarding glycosylation-dependent metastasis suppression.
This polyclonal knockout product is suited for diverse experimental applications. Researchers can perform lectin-based flow cytometry and metabolic labeling with azido sugars to profile cell surface glycans, alongside Western blotting to detect glycosylated proteins. Cell adhesion to laminin or fibronectin and transwell migration/invasion assays enable functional phenotyping. RT-qPCR analysis of EMT markers and phospho-signaling readouts of FAK allow mechanistic dissection. Use extends to functional glycosyltransferase studies and screening of anti-metastatic compounds targeting glycosylation. For further information, please contact Ascent Research.
